vs
BillionToOne, Inc.（BLLN）与牛津地产（IIPR）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是牛津地产的1.3倍（$83.5M vs $66.7M），牛津地产净利率更高（47.8% vs 6.8%，领先40.9%），BillionToOne, Inc.同比增速更快（117.4% vs -13.1%）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
牛津地产是一家加拿大跨国企业，业务涵盖房地产投资、开发与物业管理。其投资组合包含写字楼、零售、工业、多户住宅、生命科学及酒店类资产。该公司1960年以私营企业形式创立，自2003年起成为安大略省市政雇员退休系统（OMERS）的全资子公司，总部设于多伦多，在纽约、伦敦、澳大利亚、新加坡及卢森堡均设有区域总部。
BLLN vs IIPR — 直观对比
营收规模更大
BLLN
是对方的1.3倍
$66.7M
营收增速更快
BLLN
高出130.5%
-13.1%
净利率更高
IIPR
高出40.9%
6.8%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $66.7M |
| 净利润 | $5.7M | $31.8M |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | 47.8% |
| 净利率 | 6.8% | 47.8% |
| 营收同比 | 117.4% | -13.1% |
| 净利润同比 | 138.3% | -20.4% |
| 每股收益（稀释后） | $0.10 | $1.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNIIPR
| Q4 25 | — | $66.7M | ||
| Q3 25 | $83.5M | $64.7M | ||
| Q2 25 | — | $62.9M | ||
| Q1 25 | — | $71.7M | ||
| Q4 24 | $45.1M | $76.7M | ||
| Q3 24 | $38.4M | $76.5M | ||
| Q2 24 | — | $79.8M | ||
| Q1 24 | — | $75.5M |
净利润BLLNIIPR
| Q4 25 | — | $31.8M | ||
| Q3 25 | $5.7M | $29.3M | ||
| Q2 25 | — | $26.0M | ||
| Q1 25 | — | $31.1M | ||
| Q4 24 | $-11.5M | $40.0M | ||
| Q3 24 | $-14.9M | $40.2M | ||
| Q2 24 | — | $42.0M | ||
| Q1 24 | — | $39.4M |
毛利率BLLNIIPR
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 57.1% | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BLLNIIPR
| Q4 25 | — | 47.8% | ||
| Q3 25 | 11.5% | 45.5% | ||
| Q2 25 | — | 45.9% | ||
| Q1 25 | — | 47.4% | ||
| Q4 24 | 17.0% | 54.7% | ||
| Q3 24 | -32.9% | 54.8% | ||
| Q2 24 | — | 53.1% | ||
| Q1 24 | — | 55.7% |
净利率BLLNIIPR
| Q4 25 | — | 47.8% | ||
| Q3 25 | 6.8% | 45.3% | ||
| Q2 25 | — | 41.4% | ||
| Q1 25 | — | 43.3% | ||
| Q4 24 | -25.5% | 52.2% | ||
| Q3 24 | -38.8% | 52.6% | ||
| Q2 24 | — | 52.6% | ||
| Q1 24 | — | 52.3% |
每股收益（稀释后）BLLNIIPR
| Q4 25 | — | $1.07 | ||
| Q3 25 | $0.10 | $0.97 | ||
| Q2 25 | — | $0.86 | ||
| Q1 25 | — | $1.03 | ||
| Q4 24 | $-1.13 | $1.35 | ||
| Q3 24 | $-1.47 | $1.37 | ||
| Q2 24 | — | $1.44 | ||
| Q1 24 | — | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $47.6M |
| 总债务越低越好 | $55.0M | $393.7M |
| 股东权益账面价值 | $-239.5M | $1.8B |
| 总资产 | $327.5M | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
现金及短期投资BLLNIIPR
| Q4 25 | — | $47.6M | ||
| Q3 25 | $195.2M | $41.9M | ||
| Q2 25 | — | $104.9M | ||
| Q1 25 | — | $133.3M | ||
| Q4 24 | $191.5M | $151.2M | ||
| Q3 24 | — | $172.4M | ||
| Q2 24 | — | $160.9M | ||
| Q1 24 | — | $173.5M |
总债务BLLNIIPR
| Q4 25 | — | $393.7M | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $51.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNIIPR
| Q4 25 | — | $1.8B | ||
| Q3 25 | $-239.5M | $1.9B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $-251.7M | $1.9B | ||
| Q3 24 | $-242.9M | $1.9B | ||
| Q2 24 | — | $1.9B | ||
| Q1 24 | — | $2.0B |
总资产BLLNIIPR
| Q4 25 | — | $2.4B | ||
| Q3 25 | $327.5M | $2.3B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.4B | ||
| Q4 24 | $302.1M | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $2.4B |
负债/权益比BLLNIIPR
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $198.2M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | — |
| 自由现金流率自由现金流/营收 | 7.7% | — |
| 资本支出强度资本支出/营收 | 8.8% | — |
| 现金转化率经营现金流/净利润 | 2.42× | 6.22× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BLLNIIPR
| Q4 25 | — | $198.2M | ||
| Q3 25 | $13.8M | $45.6M | ||
| Q2 25 | — | $48.4M | ||
| Q1 25 | — | $54.2M | ||
| Q4 24 | — | $258.4M | ||
| Q3 24 | — | $64.9M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $71.6M |
自由现金流BLLNIIPR
| Q4 25 | — | — | ||
| Q3 25 | $6.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
自由现金流率BLLNIIPR
| Q4 25 | — | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度BLLNIIPR
| Q4 25 | — | — | ||
| Q3 25 | 8.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金转化率BLLNIIPR
| Q4 25 | — | 6.22× | ||
| Q3 25 | 2.42× | 1.56× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | — | 1.75× | ||
| Q4 24 | — | 6.46× | ||
| Q3 24 | — | 1.61× | ||
| Q2 24 | — | 1.53× | ||
| Q1 24 | — | 1.82× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
IIPR
暂无分部数据
